Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

HOTTINGER, A F, et al.

Abstract

Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.

Reference


PMID : 24786603
DOI : 10.1038/bjc.2014.209
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma


Correction to: British Journal of Cancer (2014) 110, 2655–2661. doi:10.1038/bjc.2014.209; published online 1 May 2014

Following the publication of this manuscript, it was recognised that an author name had been provided incorrectly. The correct name is A Ben Aissa. This name is now given in the author list above.

This work is published under the BJC's standard license to publish agreement. After 12 months the license terms will change to a Creative Commons AttributionNonCommercial-Share Alike 4.0 Unported License.